NurExone Announces Clinical Trial Plans for Acute Spinal Cord Injury Therapy at Annual Meeting of American Spinal Injury Association
TORONTO and HAIFA, Israel, May 30, 2025 (GLOBE NEWSWIRE) — NurExone Biologic Inc. (TSXV: NRX) (OTCQB: NRXBF) (FSE: J90) (“NurExone” or the “Company”) is pleased to announce that Professor Nahshon Knoller M.D., senior clinical advisor to the Company, will be presenting at the prestigious annual meeting of the American Spinal Injury
May 30, 2025